

# Penny Nymark

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4040727/penny-nymark-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42  
papers

1,120  
citations

21  
h-index

33  
g-index

59  
ext. papers

1,365  
ext. citations

6.6  
avg, IF

3.99  
L-index

#	Paper	IF	Citations
42	A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 849640	5.3	0
41	ELIXIR and Toxicology: a community in development. <i>F1000Research</i> , <b>2021</b> , 10, 1129	3.6	0
40	Reliable Surface Analysis Data of Nanomaterials in Support of Risk Assessment Based on Minimum Information Requirements. <i>Nanomaterials</i> , <b>2021</b> , 11,	5.4	3
39	Adverse Outcome Pathway Development for Assessment of Lung Carcinogenicity by Nanoparticles.. <i>Frontiers in Toxicology</i> , <b>2021</b> , 3, 653386	1.6	6
38	Towards FAIR nanosafety data. <i>Nature Nanotechnology</i> , <b>2021</b> , 16, 644-654	28.7	23
37	Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 638605	6	3
36	In Vitro Three-Dimensional Liver Models for Nanomaterial DNA Damage Assessment. <i>Small</i> , <b>2021</b> , 17, e2006055	11	8
35	Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints. <i>Small</i> , <b>2021</b> , 17, e2007628	11	11
34	FAIRification of nanosafety data to improve applicability of (Q)SAR approaches: A case study on Comet assay genotoxicity data. <i>Computational Toxicology</i> , <b>2021</b> , 20, 100190	3.1	1
33	Reply to: Prospects and challenges for FAIR toxicogenomics data.. <i>Nature Nanotechnology</i> , <b>2021</b> ,	28.7	1
32	Transcriptomics in Toxicogenomics, Part II: Preprocessing and Differential Expression Analysis for High Quality Data. <i>Nanomaterials</i> , <b>2020</b> , 10,	5.4	16
31	Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale. <i>Particle and Fibre Toxicology</i> , <b>2020</b> , 17, 16	8.4	68
30	NanoSolveIT Project: Driving nanoinformatics research to develop innovative and integrated tools for nanosafety assessment. <i>Computational and Structural Biotechnology Journal</i> , <b>2020</b> , 18, 583-602	6.8	41
29	Transcriptomics in Toxicogenomics, Part III: Data Modelling for Risk Assessment. <i>Nanomaterials</i> , <b>2020</b> , 10,	5.4	19
28	Transcriptomics in Toxicogenomics, Part I: Experimental Design, Technologies, Publicly Available Data, and Regulatory Aspects. <i>Nanomaterials</i> , <b>2020</b> , 10,	5.4	18
27	Lung Cancer: Molecular Markers of Occupational Carcinogens <b>2020</b> , 227-238		
26	Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices. <i>Small</i> , <b>2020</b> , 16, e1904749	11	24

25	Nanomaterial grouping: Existing approaches and future recommendations. <i>NanoImpact</i> , <b>2019</b> , 16, 100183-26	3.6	32
24	Safe innovation approach: Towards an agile system for dealing with innovations. <i>Materials Today Communications</i> , <b>2019</b> , 20, 100548	2.5	32
23	Insights into possibilities for grouping and read-across for nanomaterials in EU chemicals legislation. <i>Nanotoxicology</i> , <b>2019</b> , 13, 119-141	5.3	21
22	Toxic and Genomic Influences of Inhaled Nanomaterials as a Basis for Predicting Adverse Outcome. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, S91-S97	4.7	16
21	toxFlow: A Web-Based Application for Read-Across Toxicity Prediction Using Omics and Physicochemical Data. <i>Journal of Chemical Information and Modeling</i> , <b>2018</b> , 58, 543-549	6.1	15
20	A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions. <i>Toxicological Sciences</i> , <b>2018</b> , 162, 264-275	4.4	43
19	Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials. <i>Frontiers in Genetics</i> , <b>2018</b> , 9, 661	4.5	20
18	Enriching Nanomaterials Omics Data: An Integration Technique to Generate Biological Descriptors. <i>Small Methods</i> , <b>2017</b> , 1, 1700139	12.8	9
17	In vitro and in vivo genotoxic effects of straight versus tangled multi-walled carbon nanotubes. <i>Nanotoxicology</i> , <b>2016</b> , 10, 794-806	5.3	47
16	Extensive temporal transcriptome and microRNA analyses identify molecular mechanisms underlying mitochondrial dysfunction induced by multi-walled carbon nanotubes in human lung cells. <i>Nanotoxicology</i> , <b>2015</b> , 9, 624-35	5.3	24
15	Toward the Replacement of Animal Experiments through the Bioinformatics-driven Analysis of Omics Data from Human Cell Cultures. <i>ATLA Alternatives To Laboratory Animals</i> , <b>2015</b> , 43, 325-32	2.1	27
14	Free radical scavenging and formation by multi-walled carbon nanotubes in cell free conditions and in human bronchial epithelial cells. <i>Particle and Fibre Toxicology</i> , <b>2014</b> , 11, 4	8.4	43
13	Genotoxicity of polyvinylpyrrolidone-coated silver nanoparticles in BEAS 2B cells. <i>Toxicology</i> , <b>2013</b> , 313, 38-48	4.4	85
12	Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients. <i>Molecular Oncology</i> , <b>2013</b> , 7, 29-40	7.9	18
11	Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 585-97	5	103
10	Tumors of the Lung <b>2010</b> , 415-428		
9	DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 1336-42	8.7	26
8	Molecular alterations at 9q33.1 and polyploidy in asbestos-related lung cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 468-75	12.9	18

7	Molecular and genetic changes in asbestos-related lung cancer. <i>Cancer Letters</i> , <b>2008</b> , 265, 1-15	9.9	43
6	Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. <i>Carcinogenesis</i> , <b>2008</b> , 29, 913-7	4.6	28
5	Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. <i>Oncogene</i> , <b>2007</b> , 26, 4730-7	9.2	40
4	Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. <i>BMC Genomics</i> , <b>2007</b> , 8, 62	4.5	60
3	Identification of specific gene copy number changes in asbestos-related lung cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 5737-43	10.1	52
2	CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 42, 193-9	5	70
1	Tumors of the lung361-372		